Retrospective cohort study to assess the association between treatment with tocilizumab and mortality among mechanically ventilated patients with COVID-19.
Jacek SkarbinskiLiyan LiuVennis HongLaura B AmsdenBruce H FiremanVincent M YauDevin IncertiLei QianHeidi FischerBradley K AckersonSally F ShawSara Y TartofPublished in: BMJ open (2022)
Among mechanically ventilated patients with COVID-19, the risk of death in the 28-day follow-up period was similar, but time-to-extubation and time-to-hospital-discharge were longer in patients who received tocilizumab within 10 days of initiation of IMV compared with patients who did not receive tocilizumab.
Keyphrases
- rheumatoid arthritis
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- intensive care unit
- acute respiratory distress syndrome
- disease activity
- mechanical ventilation
- cardiac surgery
- extracorporeal membrane oxygenation
- risk factors
- type diabetes
- systemic lupus erythematosus
- cardiovascular disease
- acute kidney injury
- respiratory failure
- smoking cessation
- replacement therapy